Keros Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:KROS) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Cash from operating activities -46.01 M161.17 M-29.62 M3.25 M-27.29 M 107.5 M Cash from investing activities -289 K-565 K-720 K-132 K-134 K -1.55 M Cash from financing activities 75.54 M4 00017 K140 K-378.63 M -378.47 M Free cash flow -46.3 M160.61 M-30.34 M3.12 M-27.43 M 105.95 M

Haberler

Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?

KROS: Is the Discount Book Value a Value Trap?

KROS Stock: What to Know About Rinvatercept in DMD

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?

Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?

Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates

Keros kazancı $0,16 ile beklentilere göre daha kötü, kâr ise beklentilere göre düşük

Keros earnings missed by $0.16, revenue fell short of estimates

Keros Therapeutics eski Lyell CFO’sunu yönetim kuruluna aldı

Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?

Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?